Prevention of infection in patients with cirrhosis with probiotic Lactobacillus casei Shirota
| ISRCTN | ISRCTN62619436 |
|---|---|
| DOI | https://doi.org/10.1186/ISRCTN62619436 |
| Secondary identifying numbers | 02/0012 |
- Submission date
- 26/03/2019
- Registration date
- 08/04/2019
- Last edited
- 12/06/2023
- Recruitment status
- No longer recruiting
- Overall study status
- Completed
- Condition category
- Digestive System
Plain English summary of protocol
Background and study aims
Patients with cirrhosis (scarring) of the liver are prone to infection. Bacteria which are normally present and confined to the bowel in health can get into the bloodstream in patients with cirrhosis and cause serious and often life-threatening infection with devastating effects on liver function. This is thought to be due to an imbalance in helpful and harmful bacteria in the bowel and problems with the body’s immune defence system. Researchers have shown that probiotics, which are ‘bio-friendly’ food supplements, can alter gut flora and have a number of beneficial effects in cirrhosis. These include an improvement in markers of liver damage and restored function of important immune cells in patients with alcoholic liver disease. They have also been shown to improve outcome and reduce the risk of death in clinical conditions which have a similar basis to chronic liver disease. Probiotics could be very beneficial not only for in-patients who are acutely unwell, but also for out-patients to limit the likelihood of deterioration. This study is designed to assess the effects of a longer treatment with the probiotic Lactobacillus casei Shirota on infection rates, immune function, gut function and quality of life improvement in patients with any form of cirrhosis.
Who can participate?
Patients aged 18-78 with cirrhosis
What does the study involve?
Participants are randomly allocated into two groups. Group 1 receive Yakult yoghurt 3 bottles a day (65 ml each, containing Lactobacillus casei Shirota). Group 2 receive a similar looking and tasting placebo without bacteria. Participants are treated for 6 months. Blood samples are taken at the initial screening visit and at days 0, 14, months 1, 3, 6, 9, and 12. Routine tests are performed. Additional blood samples are collected at day 0, months 1, 6 and 12.
What are the possible benefits and risks of participating?
Previous studies suggest that patients with liver disease do benefit from probiotic therapy in aspects of liver and immune function. Longer treatment with probiotics could reduce significant infection, improve immune function and quality of life. This study is being undertaken if there is any benefit. Probiotic treatment is a food supplement which is associated with very few risks. We would however avoid using it in patients with inflammation of the pancreas. The main side effects of the supplement are a mild laxative effect and an increase in flatulence, the latter being regarded as a positive indicator of a high degree of fermentation, a sign that the supplements are working.
Where is the study run from?
University College London (UK)
When is the study starting and how long is it expected to run for?
August 2010 to February 2017
Who is funding the study?
Yakult
Who is the main contact?
Prof. Rajiv Jalan
r.jalan@ucl.ac.uk
Contact information
Scientific
Institute for Liver and Digestive Health
Upper third floor
UCL Medical School
Royal Free Campus
Rowland Hill Street
London
NW3 2PF
United Kingdom
 ORCID ID |
0000-0002-7747-4015 |
|---|---|
| Phone | +44 (0)20743332795 |
| r.jalan@ucl.ac.uk |
Study information
| Study design | Multi-centre double-blind placebo-controlled randomised controlled study |
|---|---|
| Primary study design | Interventional |
| Secondary study design | Randomised controlled trial |
| Study setting(s) | Hospital |
| Study type | Treatment |
| Participant information sheet | Not available in web format |
| Scientific title | Prevention of infection in cirrhosis with Lactobacillus casei Shirota: a randomised double-blinded placebo-controlled study |
| Study objectives | Administration of Lactobacillus casei Shirota in patients with liver cirrhosis will improve innate immune function through alteration of the gut bacterial flora and gut barrier integrity. |
| Ethics approval(s) | Approved by the Joint UCL/UCLH Committees on the Ethics of Human Research: Committee Alpha Neil Hubbard, Research Portfolio Manager, Theme 4 (NIHR Divisions 6), Royal Free London NHS Foundation Trust, Royal Free Hospital, Research & Development Office, Lower Ground Floor, Room LG/306, Pond Street, London, NW3 2QG; Tel: +44 (0)20 7794 0500 ext: 36316; Email: n.hubbard@nhs.net), REC Ref: 02/0012 Ethics Committee at Basildon Hospital (James Hampton-Till, Director of Research, Basildon & Thurrock University Hospitals NHS Foundation Trust, Nether Mayne, Basildon, Essex, SS16 5NL; Tel: +44 (0)8451553111 ext 8988) |
| Health condition(s) or problem(s) studied | Cirrhosis |
| Intervention | 92 patients will be randomised into two groups: Group 1: Oral Yakult yoghurt 3 bottles a day (65 ml each, containing Lactobacillus casei Shirota at a concentration of 108/ml) Group 2: Similar looking and tasting oral placebo without bacteria (3 bottles per day) The recruited patients will be treated for 6 months. Blood will be taken at the initial screening visit and at days 0, 14, months 1, 3, 6, 9, 12. Routine biochemistry and haematology will be performed. Additional blood will be collected at day 0, months 1, 6 and 12. Effect of serum on the function of normal neutrophils will be determined cytokine concentrations, measures of bacterial translocation and intestinal permeability. Urine collected will be used for further metabolic profiling. |
| Intervention type | Supplement |
| Primary outcome measure | 1. Neutrophil function assessed using phagoburst and phagotest at day 0, months 1, 6 and 12 2. Incidence of significant infection documented at time of clinical assessments at day 0, day 14, months 1, 3, 6, 9, 12 |
| Secondary outcome measures | 1. Gut barrier function assessed using lactulose/rhamnose/xylose intestinal permeability assay at day 0, months 1, 6 2. Inflammatory, cellular and humoral response assessed using luminex at day 0, months 1,6,12 3. Quality of life assessed using SF-36 at days 0, 14, months 1, 3, 6, 9, 12 |
| Overall study start date | 12/08/2010 |
| Completion date | 02/02/2017 |
Eligibility
| Participant type(s) | Patient |
|---|---|
| Age group | Adult |
| Lower age limit | 18 Years |
| Upper age limit | 78 Years |
| Sex | Both |
| Target number of participants | 92 |
| Total final enrolment | 92 |
| Key inclusion criteria | 1. Patients aged between 18-78 years 2. Clinical and radiological evidence of cirrhosis, and/or biopsy proven liver cirrhosis of any cause 3. Informed consent 4. Abstinence from alcohol for > 2 weeks at the time of screening for inclusion |
| Key exclusion criteria | 1. Pugh score > 10 2. Clinical evidence of active infection 3. Antibiotic treatment within 7 days prior to enrolment 4. Gastrointestinal haemorrhage within previous 2 weeks 5. Use of immunomodulating agents within previous month (steroids etc) 6. Use of proton pump inhibitors for preceding two weeks 7. Concomitant use of supplements (pre-, pro-, or synbiotics) likely to influence the study 8. Renal failure (such as hepatorenal syndrome), creatinine >150 mmol/l 9. Hepatic encephalopathy II to IV 10. Pancreatitis 11. Other organ failure 12. Hepatic or extra-hepatic malignancy 13. Pregnancy |
| Date of first enrolment | 03/05/2011 |
| Date of final enrolment | 03/04/2014 |
Locations
Countries of recruitment
- England
- United Kingdom
Study participating centres
Hampstead
London
NW3 2QG
United Kingdom
Basildon
SS16 5NL
United Kingdom
Sponsor information
University/education
1st Floor, Maple House
149 Tottenham Court Road
London
W1T 7DN
England
United Kingdom
| Phone | +44 (0)845 155 5000 ext 5199 |
|---|---|
| david.wilson@ucl.ac.uk | |
"ROR" |
https://ror.org/02jx3x895 |
Funders
Funder type
Industry
No information available
Results and Publications
| Intention to publish date | 31/12/2019 |
|---|---|
| Individual participant data (IPD) Intention to share | No |
| IPD sharing plan summary | Data sharing statement to be made available at a later date |
| Publication and dissemination plan | Planned publication in peer-reviewed journal in 2019. |
| IPD sharing plan | The data sharing plans for the current study are unknown and will be made available at a later date. |
Study outputs
| Output type | Details | Date created | Date added | Peer reviewed? | Patient-facing? |
|---|---|---|---|---|---|
| Results article | 02/06/2020 | 12/06/2023 | Yes | No |
Editorial Notes
12/06/2023: The following changes were made to the trial record:
1. Publication reference added.
2. The total final enrolment was added.
05/04/2019: Trial's existence confirmed by ethics committee.
